All In Biotech

Drug Trial Radar · NCT03911388

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Sep 12, 2019

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cannonball Kids' Cancer Foundation; Treovir, Inc
First posted
Apr 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 36 months, up to 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD

Conditions

  • Neoplasms, Brain
  • Glioblastoma Multiforme
  • Glioblastoma of Cerebellum
  • Neoplasms
  • Astrocytoma
  • Astrocytoma, Cerebellar
  • Neuroectodermal Tumors
  • Neuroectodermal Tumors, Primitive
  • Cerebellar PNET, Childhood
  • Cerebellar Neoplasms
  • Cerebellar Neoplasms, Primary
  • Cerebellar Neoplasm, Malignant
  • Cerebellar Neoplasm Malignant Primary
  • Neoplasm Metastases
  • Neoplasm Malignant
  • Neoplasms, Neuroepithelial
  • Neoplasms, Germ Cell and Embryonal
  • Neoplasms by Histologic Type
  • Neoplasms, Glandular and Epithelial
  • Neoplasms, Nerve Tissue
  • Central Nervous System Neoplasms, Primary
  • Central Nervous System Neoplasms, Malignant
  • Nervous System Neoplasms
  • Neoplasms by Site
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Medulloblastoma Recurrent
  • HSV
  • Virus
  • Pediatric Brain Tumor
  • Nervous System Cancer
  • Primitive Neuroectodermal Tumor (PNET) of Cerebellum

Interventions

  • G207Biological

    Single dose of G207 infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor (which includes progressive leptomeningeal disease or any site of gross tumor progressing in the brain parenchyma) within 24 hours of virus inoculation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability as Measured by Frequency of Grade 3 or Above Adverse EventsTime frame: Baseline to 15 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Recruiting

  • Siteman Cancer Center at Washington University

    St Louis, Missouri · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.